On Wednesday, Shares of Great Basin Scientific Inc (NASDAQ:GBSN), subtract -55.41% and closed at $0.330 in the last trading session. The last trading range of the stock ranges between $0.32 and $0.70. The company’s Market capitalization is $265,133.00 Billion with the total Outstanding Shares of 803,437.00. Great Basin Scientific, Inc., a molecular diagnostic testing company, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections. The companys platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman. The companys assays in clinical trials include Staphylococcus identification and resistance blood infection panel that is designed to identify species of staphylococcus infections, detect the mecA gene that confers drug resistance directly from positive blood cultures, and provide information on the antibiotic resistance profile of the bacteria; and Shiga toxin producing Escherichia coli (E. coli) test that identifies shiga toxin produced by E. coli. Its assays under development include Staphyloccocus aureus (SA) pre-surgical nasal screen, a rapid test for the presence of SA in the nasal passages of a pre-surgical patient; Stool bacterial pathogenic panel, which is designed to detect the causes of food poisoning; Candida blood infections panel that is designed to identify the five species of Candida directly from positive blood cultures; Pertussis test for contagious respiratory disease caused by the bacterium Bordetella pertussis; and CT/NG test for chlamydia tracomatis/neisseria gonorrhoeae. The company sells its diagnostic tests through a direct sales force in the United States, in addition to through distributors in the European Union and New Zealand.
Resolute Energy Corp (NYSE:REN), jumped 19.55% and closed at $30.70 in the last trading session. The last trading range of the stock ranges between $28.11 and $30.85. The company’s Market capitalization is $473.02 million with the total Outstanding Shares of 15.41 million. Resolute Energy Corporation (“Resolute” or the “Company”) ( NYSE : REN ) recently stated that it has reached a definitive agreement (the “Acquisition Agreement”) with Firewheel Energy, LLC (“Firewheel”), a portfolio company of EnCap Investments, to acquire certain oil and gas properties located in Reeves County, Texas, for a purchase price of $135 million (the “Firewheel Properties”). The transaction is expected to close on October 7, 2016.
The Firewheel Properties consist of 3,293 net acres in our highly productive Delaware Basin operating area, and include interests in thirteen horizontal and fifteen vertical wells, which produce about 1,200 net Boe per day. About 95% of the acreage and substantially all of the production and proved reserves are located within the Resolute-operated Mustang project area in Reeves County. The remainder of the acreage is also in Reeves County. The Firewheel Properties contain estimated proved reserves of 6.2 MMBoe with PV-10 of $45.8 million, using strip pricing at June 30, 2016. The acquisition also includes Firewheel’s interest in the Earn-Out Agreement (to which we are also a party) with Caprock Permian Processing LLC and Caprock Field Services LLC (collectively, “Caprock”). Following the closing of the acquisition, Resolute will receive 100% of all payments from Caprock under the Earn-Out Agreement.
Eli Lilly and Co (NYSE:LLY), gained 0.79% and closed at $81.75 in the last trading session. The last trading range of the stock ranges between $81.23 and $82.09. During the 52-week trading session the minimum price at which share price traded, registered at $67.88 and reached to max level of $88.16. Eli Lilly and Company (LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical Oncology’s (ESMO) 2016 Congress in Copenhagen, October 7-11. Presentations include new data on abemaciclib, a CDK 4 and CDK 6 inhibitor, and olaratumab, a PDGFRα blocking antibody that recently received a positive CHMP opinion, in addition to data on: pemetrexed, a multi-targeted antifolate; ramucirumab, a VEGF Receptor 2 antagonist; necitumumab, an EGFR blocking antibody; and prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor. Of these presentations, four are featured in late-breaking abstracts (two on abemaciclib, and one each on pemetrexed and ramucirumab).
The presentations on pemetrexed, ramucirumab and necitumumab include data from a few of Lilly’s immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada) in trials that are evaluating these molecules in combination with Merck’s pembrolizumab. Notably, the first results from KEYNOTE-021G – which studied pembrolizumab in combination with pemetrexed-plus-carboplatin contrast to pemetrexed-plus-carboplatin alone for the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer regardless of PD-L1 expression – will be featured in the Presidential Symposium on October 9.